MKI67 and metabolic syndrome: Additionally, factors such as Ann Arbor staging (P = 0.03), Ki-67 expression level (P = 0.044), IPI score (P < 0.001), rituximab application (P = 0.014), concurrent MetS (P = 0.01), and LDH expression level (P = 0.015) were also found to be significantly correlated with PFS (Table 4).